TargetMol

BCMA72-80 acetate(2293841-58-2 free base)

Product Code:
 
TAR-TP1806L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TP1806L-1mg1mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1806L-5mg5mg£314.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1806L-10mg10mg£434.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1806L-25mg25mg£669.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1806L-50mg50mg£914.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1806L-100mg100mg£1,187.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BCMA72-80 acetate is a HLA-A2 specific B cell maturation antigen (BCMA) peptide. It is used to study multiple myeloma and tumors, which expresses B cell maturation antigen.
CAS:
TP1806L
Formula:
C61H101N13O13S
Molecular Weight:
1256.6
Purity:
0.9878
SMILES:
CC[C@H](C)[C@@H](C(O)=O)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC1=CC=CC=C1)NC([C@H](CCSC)NC([C@H](CC(C)C)NC([C@H](CC2=CC=C(O)C=C2)N)=O)=O)=O)=O)=O)=O)=O)=O.CC(O)=O

References

Bae J , Samur M , Richardson P , et al. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy[J]. Leukemia, 2019.